Cite

    Geven, C. et al. (2018). Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first‐in‐human study and during experimental human endotoxaemia in healthy subjects. British journal of clinical pharmacology. pp. 2129-2141. [Online].